このアプリのYoutube動画がある場合はURLを送信してください。詳細 »
APPLICATION INFO - iPhoneアプリの詳細情報
mAPPHemo monitors adverse effects from the use of drugs for hemophilia treatment.
Hemophilia is a congenital coagulation disorder caused by the absence or insufficient production of clotting factor VIII (FVIII) in hemophilia A and of clotting factor IX (FIX) in hemophilia B. The symptoms are excessive or unexplained bleeding whose severity generally corresponds to the extent of the FVIII/FIX deficit. Hemophilia can range from severe (spontaneous bleeding, mostly into the muscles and joints, starting in early childhood) to moderate or mild, where bleeding mostly results from injury, surgery, or invasive procedures.
Hemophilia is treated by injecting a concentrate into the bloodstream to replace the deficient clotting factor. These products are either plasma-derived or recombinant, and can be used on demand (to resolve a bleeding episode in course) or prophylactically (at regular intervals to prevent bleeding episodes). In recent years, researchers have explored innovative solutions with a view to developing a new generation of treatment products. We are living in truly historical times for hemophilia treatment, and with an ever-growing number of new drugs coming into widespread use, we need to be extra vigilant that they are safe and effective.
mAPPHemo, developed to the specifications of the Factor VIII, Factor IX and Rare Coagulation Disorders Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH), collects data on the use of these drugs and any side effects experienced by patients. It can be used by individual healthcare facilities or on a region- or nationwide level, allowing clinicians to gather data from everyday clinical practice in the same manner anywhere in the world, so outcomes across populations can be compared. This should ultimately improve patient safety by providing a snapshot of how new hemophilia drugs are being used and what adverse events are reported around the world, shedding light on new side effects and answering questions about products’ long-term safety throughout the population or in specific subgroups.
In addition to the sponsor's scientific pursuits, this project furthers implementation of European Union rules on pharmacovigilance (Directives 2010/84/EU and 2012/26/UE) and the operating procedures for drug safety described in Italy's Ministerial Decree of May 30, 2015. The rationale for the app is to strengthen the drug monitoring system of new hemophilia products that have been or will soon be authorized for sale, and to increase the involvement of patients and healthcare professionals in reporting adverse events to the authorities (Agenzia Italiana del Farmaco [AIFA] and the European Medicines Agency [EMA]).
Finally, an app for doctors and patients through which patients can fill in questionnaires about their health and physicians can check data and patient input will facilitate doctor-patient communication.
Hemophilia is a congenital coagulation disorder caused by the absence or insufficient production of clotting factor VIII (FVIII) in hemophilia A and of clotting factor IX (FIX) in hemophilia B. The symptoms are excessive or unexplained bleeding whose severity generally corresponds to the extent of the FVIII/FIX deficit. Hemophilia can range from severe (spontaneous bleeding, mostly into the muscles and joints, starting in early childhood) to moderate or mild, where bleeding mostly results from injury, surgery, or invasive procedures.
Hemophilia is treated by injecting a concentrate into the bloodstream to replace the deficient clotting factor. These products are either plasma-derived or recombinant, and can be used on demand (to resolve a bleeding episode in course) or prophylactically (at regular intervals to prevent bleeding episodes). In recent years, researchers have explored innovative solutions with a view to developing a new generation of treatment products. We are living in truly historical times for hemophilia treatment, and with an ever-growing number of new drugs coming into widespread use, we need to be extra vigilant that they are safe and effective.
mAPPHemo, developed to the specifications of the Factor VIII, Factor IX and Rare Coagulation Disorders Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH), collects data on the use of these drugs and any side effects experienced by patients. It can be used by individual healthcare facilities or on a region- or nationwide level, allowing clinicians to gather data from everyday clinical practice in the same manner anywhere in the world, so outcomes across populations can be compared. This should ultimately improve patient safety by providing a snapshot of how new hemophilia drugs are being used and what adverse events are reported around the world, shedding light on new side effects and answering questions about products’ long-term safety throughout the population or in specific subgroups.
In addition to the sponsor's scientific pursuits, this project furthers implementation of European Union rules on pharmacovigilance (Directives 2010/84/EU and 2012/26/UE) and the operating procedures for drug safety described in Italy's Ministerial Decree of May 30, 2015. The rationale for the app is to strengthen the drug monitoring system of new hemophilia products that have been or will soon be authorized for sale, and to increase the involvement of patients and healthcare professionals in reporting adverse events to the authorities (Agenzia Italiana del Farmaco [AIFA] and the European Medicines Agency [EMA]).
Finally, an app for doctors and patients through which patients can fill in questionnaires about their health and physicians can check data and patient input will facilitate doctor-patient communication.
このアプリはiPhone、iPadの両方に対応しています。
カテゴリー
メディカル
メディカル
リリース
2024/4/27
2024/4/27
バージョン
2.0
2.0
言語
サイズ
55.9 MB
55.9 MB
条件
このバージョンの新機能
For the app dedicated to clinicians:
- Possibility to validate the drug intake and the side effect reported by a patient with a single click
For the patient app:
- Inclusion of the lot number of the treatment product
- View the detail of your reports
- C
For the app dedicated to clinicians:
- Possibility to validate the drug intake and the side effect reported by a patient with a single click
For the patient app:
- Inclusion of the lot number of the treatment product
- View the detail of your reports
- C
» 目的別iPhoneアプリ検索
- 辞書 » 日本語対応の辞書 » 英和辞典
- 学習 » 英単語 » 英会話 » クイズで楽しく
- スケジュール » 管理 » Googleカレンダー
たまひよ 妊娠・育児の赤ちゃんとママパパ応援アプリ まいにち..
Benesse Corporation無料無料 赤ちゃん名づけ 400万人の妊婦さんが子供の名付けで利..
Recstu Inc.無料第76回日本臨床外科学会総会 Mobile Planner
Japan Convention Services, Inc..無料陣痛時計
Simple Beep無料Yahoo!家庭の医学 - 症状や治療法を解説
Yahoo Japan Corp.無料たまひよ妊娠カウンター【たまプレ】
Benesse Corporation無料ナスカレ≪看護師のシフト表≫ナースのシフト共有カレンダーアプ..
株式会社クイック無料ストレススキャン カメラで手軽にストレスチェック!
Stress Scan Inc.無料赤ちゃん泣き止み音アプリ
BookLive Co., Ltd.無料きほんの離乳食 管理栄養士が監修したレシピが300種類以上!
Palsystem Consumers' Co-operat..無料
CatchApp新着アプリレビュー
様々な楽しみ方で運転士として成長していく鉄道運転士育成RPG「プラチナ・トレイン(プラトレ) 日本縦断てつどうの旅」
2016-05-17 00:00
日本語にはない英語発音のリスニングを楽しく学べる「発音どっち?英語リスニング 」
2014-12-20 12:00
指先の瞬発力が試されるカジュアルゲーム「早撃ちパニック」をリリース!
2014-12-08 15:21
新着アプリ動画